SCHEMBL13286804

SCHEMBL13286804

O=C(Oc1ccc(OC(=O)c2cc(O)c(O)c(O)c2)cc1)c1cc(O)c(O)c(O)c1

nearest known ligand 0.81

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NSD2 O96028 1/20 0.81
SERPINE1 P05121 10/20 0.66
POLB P06746 2/20 0.58
POLA1 P09884 1/20 0.58
ANTXR2 P58335 1/20 0.58
KDM4E B2RXH2 2/20 0.57
LMNA P02545 2/20 0.57
FUT7 Q11130 2/20 0.57
TDP1 Q9NUW8 2/20 0.57
GAA P10253 1/20 0.57
NFKB1 P19838 1/20 0.57
XDH P47989 1/20 0.57
GFER P55789 1/20 0.57
NFKB2 Q00653 1/20 0.57
RELA Q04206 1/20 0.57
L3MBTL1 Q9Y468 1/20 0.57
HSD17B10 Q99714 2/20 0.50
ESR1 P03372 1/20 0.50
CA12 O43570 1/20 0.48
ALDH1A1 P00352 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3006067 0.94 NSD2 (0.73) NSD2SERPINE1POLBPOLA1ANTXR2
SCHEMBL5011535 0.91 NSD2 (0.74) NSD2SERPINE1POLBPOLA1ANTXR2
SCHEMBL18993362 0.91 NSD2 (0.69) NSD2SERPINE1POLBPOLA1ANTXR2
SCHEMBL4738042 0.91 NSD2 (0.69) NSD2SERPINE1POLBPOLA1ANTXR2
SCHEMBL2495353 0.90 NSD2 (1.00) NSD2SERPINE1POLBPOLA1ANTXR2
SCHEMBL3001607 0.90 NSD2 (0.68) NSD2SERPINE1POLBPOLA1ANTXR2
SCHEMBL31322154 0.89 NSD2 (0.67) NSD2SERPINE1POLBPOLA1ANTXR2
SCHEMBL9967347 0.89 NSD2 (0.71) NSD2SERPINE1POLBPOLA1ANTXR2
SCHEMBL4736293 0.88 NSD2 (0.65) NSD2SERPINE1POLBPOLA1ANTXR2
SCHEMBL27592785 0.88 NSD2 (0.65) NSD2SERPINE1POLBPOLA1ANTXR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230322837-A1 PREPARATION METHOD FOR AND APPLICATION OF CLASS OF STELLATE BIFUNCTIONAL COMPOUNDS TARGETING SPIKE PROTEIN AGAINST RESPIRATORY TRACT INFECTION VIRUS AND SALT THEREOF SHENZHEN CELL INSPIRE PHARMACEUTICAL DEVELOPMENT CO., LTD. (CN) 2023-10-12 US disclosed
EP-4253394-A1 PREPARATION METHOD FOR AND APPLICATION OF CLASS OF STELLATE BIFUNCTIONAL COMPOUNDS TARGETING SPIKE PROTEIN AGAINST RESPIRATORY TRACT INFECTION VIRUS AND SALT THEREOF Shenzhen Cell Inspire Pharmaceutical Development Co., Ltd. (CN) 2023-10-04 EP disclosed
US-9527878-B2 Plasminogen activator inhibitor-1 inhibitors and methods of use thereof to modulate lipid metabolism THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) 2016-12-27 US disclosed
US-9527878-B2 Plasminogen activator inhibitor-1 inhibitors and methods of use thereof to modulate lipid metabolism THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) 2016-12-27 US disclosed
US-20160009748-A1 PLASMINOGEN ACTIVATOR INHIBITOR-1 INHIBITORS AND METHODS OF USE THEREOF TO MODULATE LIPID METABOLISM THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) 2016-01-14 US disclosed
US-20160009748-A1 PLASMINOGEN ACTIVATOR INHIBITOR-1 INHIBITORS AND METHODS OF USE THEREOF TO MODULATE LIPID METABOLISM THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) 2016-01-14 US disclosed
US-9120744-B2 Plasminogen activator inhibitor-1 inhibitors and methods of use thereof to modulate lipid metabolism THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) 2015-09-01 US disclosed
US-9120744-B2 Plasminogen activator inhibitor-1 inhibitors and methods of use thereof to modulate lipid metabolism THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) 2015-09-01 US disclosed
US-20100137194-A1 Plasminogen Activator Inhibitor-1 Inhibitors and Methods of Use Thereof to Modulate Lipid Metabolism THE REGENTS OF THE UNIVERSITY OF MICHIGAN 2010-06-03 US disclosed
US-20100137194-A1 Plasminogen Activator Inhibitor-1 Inhibitors and Methods of Use Thereof to Modulate Lipid Metabolism THE REGENTS OF THE UNIVERSITY OF MICHIGAN 2010-06-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100137194-A1 Plasminogen Activator Inhibitor-1 Inhibitors and Methods of Use Thereof to Modulate Lipid Metabolism SERPINE1, PLAT, SERPINB1 NSD2 4609/4885SERPINE1 1/4885POLB 3604/4885
US-20160009748-A1 PLASMINOGEN ACTIVATOR INHIBITOR-1 INHIBITORS AND METHODS OF USE THEREOF TO MODULATE LIPID METABOLISM SERPINE1, PLAT, SERPINB1 NSD2 4609/4885SERPINE1 1/4885POLB 3604/4885
US-20230322837-A1 PREPARATION METHOD FOR AND APPLICATION OF CLASS OF STELLATE BIFUNCTIONAL COMPOUNDS TARGETING SPIKE PROTEIN AGAINST RESPIRATORY TRACT INFECTION VIRUS AND SALT THEREOF PROC, TMPRSS2, ACE2 NSD2 3338/4885SERPINE1 44/4885POLB 4633/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.